Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Baudin, E.
Right arrow Articles by Schlumberger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baudin, E.
Right arrow Articles by Schlumberger, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1806-1809, 2002
© 2002 European Society for Medical Oncology

Original Paper

Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma

E. Baudin1,+, C. Docao1, C. Gicquel2, G. Vassal3, A. Bachelot1, A. Penfornis4 and M. Schlumberger1

1 Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave-Roussy, Villejuif; 2 Laboratoire d’Explorations Fonctionnelles Endocriniennes, Hôpital Armand Trousseau, Paris; 3 Département de Pédiatrie et Laboratoire de Pharmacotoxicologie et Pharmacogénétique, Institut Gustave-Roussy, Villejuif; 4 Service d’Endocrinologie, Centre Hospitalier et Universitaire de Besançon, Besançon, France

Received 7 May 2002; accepted 22 May 2002

Background:

Complete responses are rare after medical treatment of adrenocortical tumors. We performed a single center prospective study of the antitumor effect of irinotecan (CPT-11) in patients with metastatic adrenocortical cancer.

Patients and methods:

Since 1999, all patients with advanced progressive adrenocortical carcinoma, referred to the Institut Gustave-Roussy, have been enrolled prospectively in this study. CPT-11 (250 mg/m2) was administered intravenously on day 1 in a 2-h infusion, every 14 days. World Health Organization (WHO) criteria were used to evaluate tumor response and toxicity.

Results:

During treatment, no dose or schedule modifications were made. A median of three courses were given (range 1–8), and all but two patients received at least three complete chemotherapy courses. No objective or complete responses were observed. The best response achieved was stabilization in three patients, lasting from 1.5 to 4 months. Significant toxicity occurred in two patients.

Conclusions:

Our results do not support a major role of CPT-11 in adrenocortical carcinoma.

Key words: adrenocortical carcinoma, chemotherapy, CPT-11, irinotecan


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
I G C Hermsen, H Gelderblom, J Kievit, J A Romijn, and H R Haak
Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma.
Eur. J. Endocrinol., June 1, 2008; 158(6): 911 - 919.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Quinkler, S. Hahner, S. Wortmann, S. Johanssen, P. Adam, C. Ritte, C. Strasburger, B. Allolio, and M. Fassnacht
Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2057 - 2062.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.